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Abstract 
BACKGROUND: Gastric cancer is one of the most important health issues in the world. Considering the lack of 
plenty of pre-awarenesses, the survival of gastric cancer is still quite disappointing. Methylation of PAX5 gene 
promoter is observed in most cancer cells of a human. A study has shown that PAX5 is a new tumoral suppressor 
in gastric cancer and methylation of the PAX5 promoter is associated with the survival rate of gastric cancer.  
AIM: The present research seeks to study the expression rate and methylation of the PAX5 gene in the blood of 
patients who have gastric cancer to be used as a biomarker in this type of cancer. 
MATERIAL AND METHODS: Real-time PCR technique was used to assess expression of PAX5 gene, while the 
methylation status of PAX5 gene promoter in the blood samples of people who have gastric cancer versus blood 
samples obtained from normal Iranian population was studied using MS PCR technique. 
RESULTS: The final results pointed to the fact that expression of PAX5 in blood samples obtained from those 
who have gastric cancer is much less than what is observed in normal blood samples. A significant correlation 
was also observed between expression of this gene and age and promoter methylation rate. The results of 
methylation also indicated that 28% of PAX5 gene promoters among patients were methylated, while all normal 
samples were non-methylated.  
CONCLUSION: Studying the decrease observed in PAX5 gene expression and the rise in promoter methylation 
can be utilised as a biomarker to enhance pre-awareness of gastric cancer. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Gastric cancer is the result of cancer cell 
formation on the interior lining of the stomach [1]. The 
most common form of this cancer is known as 
Adenocarcinoma [2]. Throughout the world, the gastric 
cancer is the fifth main cause of cancer and the third 
major reason for death [3]. Lack of pre-awareness 
factors and proper diagnosis are the main problems in 
treating gastric cancer [3]. PAX genes (paired box) 
are a family of genes encoding tissue-specific 
transcription factors that play a major role in adjusting 
developmental and evolutional programs [4]. Pax1, 
Pax2, Pax3, Pax4, Pax5, Pax6, Pax7, Pax8, and Pax9 
are the members of PAX gene. PAX5 gene encodes a 
family of transcription factors that regulate 
development that play a major and central role in cell 
differentiation and tissue development [4]. 
Inappropriate expression of PAX5 has been reported 
in various types of human tumours [4]. Researchers 
believe that inappropriate expression of PAX5 
contributes to Carcinogenesis and malignant 
progression of human cancers such as gastric cancer 
[5]. PAX5 suppression is closely linked with the 
hypermethylation status of the promoter, and it can be 
reconstructed through demethylation treatments [6]. 
By knocking down PAX5 trough short hairpin RNA’s, 
the survivability and reproducibility of cells rise [5]. As 
a result, PAX5 is a useful tumour suppressor in gastric 
carcinoma and diagnosis of methylated PAX5 can be 
considered an independent pre-awareness factor in 
gastric cancer.  
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The present research seeks to study the 
expression rate and methylation of PAX5 gene in the 
blood of individuals who have gastric cancer and 
compare it against normal blood samples and study 
their role as pre-awareness and diagonal factors in 
gastric cancer. We also seek to study the possible link 
between changes in the expression of this gene and 
gender, age, and methylation status.  
 
 
Materials and Method 
 
As many as 70 venous blood samples (35 
healthy samples and 35 samples obtained from those 
with gastric cancer) were obtained from Masoud 
medical diagnostic laboratory in Tehran, Iran. 18 
samples were females, and 52 samples were males.  
With due observation of the standard protocol 
of the kit, RNA extraction kit made by Sinagen Iran 
Co. (MR7713C) was used to extract Total RNA. Then 
the quality of purified RNA was studied using a 
spectrophotometer, and the optical absorption 
difference of 260 to 280 was taken into consideration. 
To synthesise cDNA, dNTP 10 Mm (1 μl), Random 
Hexamer (40 Mm) (1 μl), and Oligo dt (1 μl) obtained 
from Sinagen Co. and, finally, 10 μl purified RNA was 
added to the microtube. The resulting mixture was 
exposed to a temperature of 65℃ for 5 minutes; then 
it was exposed to a temperature of 4℃ for 1 minute. 
Next, MMULV 10 X buffer (2 μl) and MMULV (200 
U/μl) (0.5 μl) were added to this tube, and the total 
volume was increased to 20 μl using DEPC water. 
The tube was exposed to a temperature of 42℃ for 1 
hour, and then it was exposed to a temperature of 
80℃ for 5 minutes.  
To conduct SYBR Green-based Real-Time 
PCR on cDNA samples, the required primers for 
PAX5 and GAPDH gene (as internal controls) were 
designed using the sequences that exist in NCBI and 
using Annealing Primer Express software. The results 
are presented in Table 1. 
Table 1: The primers used in our research 
Primer Sequence Tm℃ Amplicon 
size(bp) 
PAX5 (F) GGACCAGCAGGACAGGTATT 59.02 118bp 
PAX5 (R) TTGGCGTTTATATTCAGCGA 59.31 118bp 
GAPDH (F) ATGGAGAAGGCTGGGGCT 62.05 124bp 
GAPDH (R) ATCTTGAGGCTGTTGTCATACTTCTC 61.62 124bp 
 
The reaction mixture consisted of 10 μl 
master mix obtained from Sinagen Co., 1 μl gene 
sample, 0.5 μl forward primer (0.4 millimolar), 0.5 μl 
reverse primer (0.4 millimolar) and 8 μl distilled water. 
The following temperature was required in this 
experiment: 95℃ (1 cycle lasting 10 minutes), 95℃ 
(40 cycles each lasting 15 seconds), 58℃ (1 minute) 
for PAX5 and 59℃ (1 minute) for GAPDH gene. 
Finally, the analysis of the data resulting from Real-
time PCR was conducted based on the threshold 
cycle obtained for the target and reference genes. To 
study the specificity of primers and make sure about 
the proliferation of exclusive components, separate 
melting curve graphs were drawn for PAX5 and 
GAPDH genes using Step One Real-Time PCR 
Systems-Applied Biosystems. The RQ of samples 
were calculated by the device, and the chart of results 
was drawn by Graph pad software (P-value < 0.0001). 
To study the presence of CPG islands in 
PAX5 gene promoter and its effect on gastric cancer, 
methylation-specific PCR (MS PCR) technique was 
used. Using DNA extraction kit made by Sinagen Co. 
(DN8118C) and the standard protocol of the kit, the 
genomic DNA was extracted from the blood of 
participants. The kit made by Thermo Scientific Co. 
(EPIJET BISULFITE CONVERSION K1461) was used 
to modify DNA. Two pairs of primers were designed 
for MS PCR reaction. One pair was used for the areas 
containing methylated cytosines beginning with G, 
and the other pair was used for non-methylated 
cytosines beginning with A (Table 2). 
Table 2: The primers designed for methylated and non-
methylated areas in MS PCR reaction 
Amplicon 
Size(bp) 
Tm℃ Sequence 
 
Primer 
 
bp 250 63 TTCGCGTATAGCGTAGAGGGTCG PAX5 MET (F) 
bp 250 62/2 AAACGTAACGAACCCGACCCG PAX5 MET (R) 
bp 250 54/7 TTTGTGTATAGTGTAGAGGGTTG PAX5 UNMET (F) 
bp 250 52/8 AAATGTAATGAACCTGACCTG PAX5 UNMET (R) 
 
MS PCR reaction was carried out by adding 
12 μl master mix, 1 μl forward primer (0.4 millimolar), 
1 μl of reverse primer (0.4 millimolar), 2 μl of modified 
DNA sample (10 ng), and 9 μl of distilled water to the 
microtube. The following plan was defined for 
reaction: exposure to a temperature of 93℃ for 3 
minutes for the initial denaturation, forty 30-second 
cycles of exposure to a temperature of 93℃, exposure 
to a temperature of 66℃ for 30 seconds, exposure to 
a temperature of 72℃ for 30 seconds, and, finally, 
exposure to a temperature of 72℃ for 5 minutes. To 
validate the product of PCR reaction, as much as 10 
μl of it was run in 1% Agarose gel. 
 
 
Results 
 
A group of 39 samples belonged to people 
older than 50 years old, while the remaining 31 
samples were obtained from people younger than 50.  
Having extracted the RNA, the quality of 
extracted RNA was reported 1.7 by comparing the 
wavelength of 260 to 280. 
Normal samples are used as references to 
compare changes in the expression rate of each gene 
compared to ill samples (Figure 1 and 2). 
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a)  
b)  
Figure 1: The linear curve of PAX5 gene proliferation in healthy and 
ill samples (a); the linear curve of GAPDH gene proliferation in 
healthy and ill samples (b) 
 
The expression rate of sick samples was 
compared against normal samples. The results 
represent the expression of the same gene compared 
to what was observed in the blood of normal people 
(Figure 3). 
A)  
B)  
Figure 2: PAX5 gene melting curve in normal and sick samples A); 
GAPDH gene melting curve in normal and sick samples B) 
 
Figure 3: An analysis of PAX5 gene expression in sick samples 
compared to controls (P-value < 0.0001) 
 
As the chart shows, most samples obtained 
from patients indicate less expression compared to 
normal samples. The normal samples are based upon 
the analysis made by the device, and all samples are 
compared against the normal samples. The least 
expression rates are observed in number 2, 4, 5, 7, 8, 
11, 13, 18, 20, 21, 22, 26, 28, 31, 33, and 35 samples. 
As it is expected from PAX5 as a tumour suppressor 
in gastric cancer, the average expression of this rate 
in normal samples is more than all samples.  
Further analysis showed that the mean 
expression rate of the PAX5 gene among patients is 
less than what is observed among normal 
participants. What this means for patients is 0.2, while 
it was 0.55 among normal people. The greater 
expression may vary based upon gender, age, and 
methylation status (P-value = 0.0378) (Figure 4). 
 
Figure 4: Mean expression of PAX5 gene in among patients and 
normal participants (P-value = 0.0378) 
 
An analysis of results has shown that the 
mean expression rate of PAX5 gene among patients 
compared to normal participants younger than 50 
years old is 1.44, while this value for those older than 
50 years old was 0.54 (P-value = 0.0159) (Figure 5). 
 
Figure 5: Mean expression rate of the PAX5 gene based upon age 
(P-value = 0.0159) 
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The mean expression rate of PAX5 gene 
among male patients has been much more than what 
was observed among the female peers. This average 
of RQ among men was 73%, while it was 66.8% 
among women. We may conclude that the expression 
rate of PAX5 among male patients was much more 
than what was observed among female patients (P-
value=0.8721) (Figure 6). 
 
 
Figure 6: Mean RQ of PAX5 gene based upon gender (P-value = 
0.8721) 
 
By conducting MS PCR using methylated 
primers on 70 samples to study the methylation status 
of PAX5 gene promoter, the band was observed in 4, 
5, 31, 33, 34, 35, 39, 41, 43, 48 that it indicates 
methylation of PAX5 gene promoter in these samples. 
The band sizes are in the range of 250 bp (Figure 7). 
 
Figure 7: A sample of MS PCR results using methylated primers. 
Presence of bands with the size of 250 bp indicates methylation of 
PAX5 gene promoter 
 
By conducting MS PCR using non-methylated 
primers on 70 samples to study the methylation status 
of PAX5 gene promoter, the band was observed in 60 
samples out of 70 samples which points to the fact 
that PAX5 gene promoter is non-methylated in these 
samples (Figure 8).  
 
Figure 8: A sample of the results of MS PCR using non-methylated 
primers. Presence of bands with a size of 250 bp indicates the fact 
that PAX5 gene promoter is non-methylated 
 
Considering the results of MS PCR test for 
PAX5 gene, it was shown that only 10 DNA samples 
(of the whole 35 DNA samples) of patients are 
methylated (28%) but all normal samples are non-
methylated. Consequently, 28% of samples for PAX5 
gene promoter are methylated. The average 
expression rate of the PAX5 gene in non-methylated 
samples was 99%, while this value in methylated 
samples is 17%. As a result, the mean expression 
rate of the PAX5 gene in non-methylated samples is 
higher than methylated samples (Figure 9).  
 
Figure 9: Mean RQ of the PAX5 gene based upon methylation 
status (P-value = 0.0409) 
 
The P-values obtained through analysis of 
changes in expression of PAX5 gene based upon 
gender, age, and methylation status are 0.8721, 
0.0159, and 0.0409 which are respectively 
insignificant, significant and significant. As a result, no 
significant correlation is observed between less 
expression of PAX5 and gender, but the correlation 
between less expression of PAX5 and age and level 
of promoter methylation is significant. 
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Discussion 
 
Gastric cancer is still the second and the most 
common reason of death caused by cancer 
throughout the world [6]. In Iran, gastric cancer has 
the greatest prevalence of all cancers among men [7]. 
Various transcriptional and regulatory factors that play 
a tumor suppressive role have been diagnosed in 
gastric cancer. For instance, PAX transcription factor 
has been diagnosed as a tumor suppressor in gastric 
cancer [8]. Other researches have pointed to the little 
or no expression of PAX5 in human cancers which 
shows PAX5 may act as a potential tumor suppressor 
in carcinogenesis [8]. Many researches have reported 
that methylation of the DNA promoter of PAX5 gene 
will result in the shutdown of PAX5 diagnosed in 
several malignancies [9]. PAX5 has recently been 
used in diagnostic predictions of gastric cancer [10]. 
Using PCR technique for proliferation of methylated 
areas, Palmisano et al showed that activation of PAX5 
gene can help neoplastic development by suppressing 
growth regulators through affecting expression of 
CD19 gene [11]. They suggested that PAX5 gene 
methylation is observed in tumors and their 
surrounding tissues and rarely in natural epithelial 
cells (assessments confirm them as intermediate 
markers in breast and lung cancers used to improve 
sensitivity and exclusiveness for development of risk 
models in order to diagnose these types of cancer) 
[11]. Using MSPCR technique and bisulfate genomic 
sequence, Liu et al., (2011) showed that PAX5 is a 
functional tumor-suppressing gene and plays a major 
role in liver carcinogenesis by direct regulation of P53 
signaling path which is usually deactivated through 
promoter methylation in Primary hepatocellular 
carcinoma tissues [12]. Using genome-wide 
methylation screening, Li et al., (2012) reported that 
suppression PAX5 is closely associated with promoter 
hypermethylation and improper expression of PAX5 in 
the shutdown cell lines of GC (AGS, BGC823) 
suppresses formation of colony and survivability of 
cells, stops cell cycle, induces apoptosis, suppresses 
cell immigration and invasion, and suppresses 
tumorigenesis in NUDE mice [13]. Using real-time 
PCR technique, a study was conducted by Liu et al 
and the results showed that PAX5 is suppressed or 
shut down in most HCC cell lines and primary tumors 
[12]. In 2014, Deng et al studied the expression and 
methylation of PAX5 gene in gastric tumor tissue and 
normal tissue for the first time. According to this 
research, mRNA expression of PAX5 gene was 
diagnosed in 25 cancerous tissues of the stomach (of 
the whole 460 cancerous tissues) and 25 healthy 
mucosal gastric tissues through RT-PCR techniques 
[14]. Important differences in mRNA expression of 
PAX5 gene were found in 25 cancerous gastric 
tissues. The mean value of the relative expression of 
mRNA in PAX5 gene in 25 cancerous gastric tissues 
was 0.836 ± 0.357, while the mean value of the 
relative expression of mRNA in PAX5 gene in 25 
normal gastric mucosal tissues was 1.759 ± 0.821. 
The mean value of the relative expression of mRNA in 
PAX5 gene in 25 cancerous gastric tissues was less 
than the 25 normal gastric mucosal tissues [14]. 
Considering the importance of PAX5 gene, the 
present research studied expression of this gene in 
the blood samples of people suffering from gastric 
cancer in Iranian population. This is the first 
comprehensive research which presents statistical 
data of PAX5 gene expression in the blood samples 
obtained from people suffering from gastric cancer in 
Iran. Using Real-Time PCR technique, the expression 
of this gene was compared accurately across the 
healthy participants and patients. Contrary to other 
studies and further to investigating the expression rate 
of PAX5 gene, the present research studied the 
methylation rate of PAX5 gene promoter and the 
correlation between methylation level and PAX5 gene 
expression simultaneously. As the data resulting from 
this research indicate, the expression rate of PAX5 in 
the blood samples obtained from patients is less than 
what is observed in normal samples. This data is in 
line with the results of a research by Deng et al., 
indicating that PAX5 gene in gastric cancer acts as a 
tumor-suppressing gene plus less expression of PAX5 
gene in tumor samples obtained from stomach [14]. A 
review of methylation status of PAX5 gene promoter 
showed that 28% of the DNA obtained from patients is 
methylated and all normal samples were non-
methylated. These results are in line with the results 
of researches conducted on tumor samples of gastric 
tissue [15]. What’s more, there is a significant 
correlation between the mean expression rate of 
PAX5 and age and methylation status of promoter; 
however, no significant correlation was observed 
between average expression rate of PAX5 gene and 
gender. All these researches were conducted on 
paraffined tissue samples; however, gastric cancer is 
not usually diagnosable in its early phases.  
As a result, studying the expression and 
methylation of the PAX5 gene in the blood of people 
who have gastric cancer shortly can be used as a 
diagnostic biomarker for gastric cancer.  
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